Eric L. Sievers.Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates[J]. Cancer Chemotherapy and Pharmacology .2000(1)Sievers, E.L. 2000 Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates Cancer Chemother. Pharmacol. 46 S...
Acute myeloid leukemia (AML) is a stubborn malignant tumor, and AML with different mutations often exhibits significant heterogeneity, which poses challenges to the treatment of AML. RUNX1 is a vital transcription component participated in regulation of blood tissue development, and mutated RUNX1 are...
Until 2000, therapy for chronic myeloid leukemia (CML) was limited to nonspecific agents such as busulfan, hydroxyurea, and interferon-alpha (IFN-a). The landscape changed dramatically with the development of small-molecule tyrosine kinase inhibitors (TKIs) that was shown to potently interfere with...
Key words: AML, Targeted therapy, Immunotherapy, Drug progress Competing interests: The authors declare that they have no competing interests. References [1] Kennedy VE, Smith CC. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies[J]. Front Oncol, 2020, 10: 6128...
John DiPersio, MD, PhD, discusses targeted therapies for myeloid malignancies using DARTs, Bites, and antibody–drug conjugates, a topic he presented during the 2019 Society for Hematologic Oncology Annual Meeting. John DiPersio, MD, PhD, chief of the Division of Oncology and direc...
The efficacy of GO as monotherapy and in combination therapy for treatment of both de novo and relapsed AML continues to be investigated. 展开 关键词: acute myeloid leukemia therapy older adults gemtuzumab ozogamicin DOI: 10.2147/CIA.S3968 被引量: 18 ...
leukemia remains incomplete, the information gained to date has had a profound impact on the way these malignancies are both diagnosed and monitored during therapy. More recently, targeted therapies have been developed against some of the identified genetic lesions. These therapies have led to ...
The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms:Moving toward an effective oral,outpatient therapy...
Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: Wikipedia In chronic leukemias, blocking the overactive kinase JAK2 by a targeted therapy approach is only mitigating the patients' symptoms, but cannot truly change the course of the disease. A study by ...
Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: Wikipedia A team of Northwestern Medicine scientists led by Ali Shilatifard, Ph.D., the Robert Francis Furchgott Professor and chair of Biochemistry and Molecular Genetics, has identified the molecular mechani...